SMS Pharma gets non-exclusive license to manufacture and supply molnupiravir through MPP

20 Jan 2022 Evaluate

SMS Pharmaceuticals has received a non?exclusive license through the Medicines Patent Pool (MPP) to manufacture molnupiravir, an investigational oral antiviral COVID?19 medicine, to increase broad access of treatment in 105 low? and middle? income countries (LMIC).

MSD, a trade name of Merck & Co., Inc, Kenilworth, NJ, USA., has entered into an agreement to license this pill for wider distribution with patent group. Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non? exclusive sublicences to manufacturers and diversify the manufacturing base for the supply of molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.

SMS Pharmaceuticals is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state?of?the?art facilities.

SMS Pharmaceuticals Share Price

316.70 -7.20 (-2.22%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×